Nothing Special   »   [go: up one dir, main page]

HK1079998A1 - 埃坡霉素在與增殖過程有關的腦病的治療中的用途 - Google Patents

埃坡霉素在與增殖過程有關的腦病的治療中的用途

Info

Publication number
HK1079998A1
HK1079998A1 HK06100157.3A HK06100157A HK1079998A1 HK 1079998 A1 HK1079998 A1 HK 1079998A1 HK 06100157 A HK06100157 A HK 06100157A HK 1079998 A1 HK1079998 A1 HK 1079998A1
Authority
HK
Hong Kong
Prior art keywords
epothilones
treatment
diseases associated
brain diseases
proliferative processes
Prior art date
Application number
HK06100157.3A
Other languages
English (en)
Inventor
羅斯瑪麗.利希特納
安德烈亞.羅特蓋里
烏爾里希.克拉爾
延斯.赫夫曼
貝恩德.布赫曼
沃爾夫岡.施韋德
維爾納.斯庫巴爾拉
Original Assignee
舍林股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27675676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1079998(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 舍林股份公司 filed Critical 舍林股份公司
Publication of HK1079998A1 publication Critical patent/HK1079998A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06100157.3A 2002-03-01 2006-01-04 埃坡霉素在與增殖過程有關的腦病的治療中的用途 HK1079998A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36106202P 2002-03-01 2002-03-01
EP02004745A EP1340498A1 (en) 2002-03-01 2002-03-01 Use of epothilones in the treatment of brain diseases associated with proliferative processes
PCT/EP2003/002085 WO2003074053A1 (en) 2002-03-01 2003-02-28 Use of epothilones in the treatment of brain diseases associated with proliferative processes

Publications (1)

Publication Number Publication Date
HK1079998A1 true HK1079998A1 (zh) 2006-04-21

Family

ID=27675676

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100157.3A HK1079998A1 (zh) 2002-03-01 2006-01-04 埃坡霉素在與增殖過程有關的腦病的治療中的用途

Country Status (23)

Country Link
US (1) US20040019088A1 (zh)
EP (2) EP1340498A1 (zh)
JP (1) JP2005525360A (zh)
KR (1) KR20040095244A (zh)
CN (1) CN100473381C (zh)
AR (1) AR038712A1 (zh)
AU (1) AU2003215618B2 (zh)
BR (1) BR0308154A (zh)
CA (1) CA2477403A1 (zh)
CR (1) CR7444A (zh)
EC (1) ECSP045340A (zh)
HK (1) HK1079998A1 (zh)
HR (1) HRP20040892A2 (zh)
IL (1) IL163752A0 (zh)
MX (1) MXPA04008450A (zh)
NO (1) NO20044175L (zh)
NZ (1) NZ546617A (zh)
PL (1) PL370768A1 (zh)
RU (1) RU2351330C2 (zh)
UA (1) UA83798C2 (zh)
WO (1) WO2003074053A1 (zh)
YU (1) YU76404A (zh)
ZA (1) ZA200407905B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
SK11452001A3 (sk) * 1999-02-11 2002-04-04 Schering Aktiengesellschaft Deriváty epotilónu, farmaceutický prípravok s ich obsahom a ich použitie
AU772750C (en) * 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2336937T3 (es) 2002-08-23 2010-04-19 Sloan-Kettering Institute For Cancer Research Sintesis de epotilonas, sus intermedios, analogos y usos.
DE10331004A1 (de) * 2003-07-03 2005-02-24 Schering Ag Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1700596A1 (en) * 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
DE102007016046A1 (de) * 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
AR071598A1 (es) * 2008-04-24 2010-06-30 Bristol Myers Squibb Co Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284529B6 (sk) * 1995-06-09 2005-05-05 Novartis Ag Deriváty rapamycínu, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a súprava alebo balenie na použitie pri imunosupresii, zápale alebo infekciách
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2282683A1 (en) * 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE368036T1 (de) * 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
ES2207015T3 (es) * 1997-12-04 2004-05-16 Bristol-Myers Squibb Company Procedimiento para la reduccion de epotilonas de oxiranilo epotilonas olefinicas.
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO1999067253A2 (en) * 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
ES2291194T3 (es) * 1999-02-18 2008-03-01 Bayer Schering Pharma Aktiengesellschaft Derivados de 16-halogeno-epotilones, procedimiento acerca de su preparacion y su utilizacion farmaceutica.
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
AU775373B2 (en) * 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
GB0013643D0 (en) * 2000-05-31 2000-07-26 Unilever Plc Targeted moieties for use in bleach catalysts
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives

Also Published As

Publication number Publication date
JP2005525360A (ja) 2005-08-25
IL163752A0 (en) 2005-12-18
ZA200407905B (en) 2006-04-26
BR0308154A (pt) 2005-01-04
EP1340498A1 (en) 2003-09-03
NZ546617A (en) 2007-12-21
CN1649587A (zh) 2005-08-03
AU2003215618A1 (en) 2003-09-16
PL370768A1 (en) 2005-05-30
RU2004129325A (ru) 2005-07-10
YU76404A (sh) 2006-08-17
EP1480643A1 (en) 2004-12-01
UA83798C2 (ru) 2008-08-26
AR038712A1 (es) 2005-01-26
HRP20040892A2 (en) 2004-12-31
WO2003074053A1 (en) 2003-09-12
US20040019088A1 (en) 2004-01-29
AU2003215618B2 (en) 2009-06-04
MXPA04008450A (es) 2005-07-13
RU2351330C2 (ru) 2009-04-10
CN100473381C (zh) 2009-04-01
NO20044175L (no) 2004-12-01
ECSP045340A (es) 2004-11-26
CR7444A (es) 2005-10-05
KR20040095244A (ko) 2004-11-12
CA2477403A1 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
IL163752A0 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
PT1613296E (pt) Métodos para o tratamento da doença de parkinson
EP1641378A4 (en) METHOD AND DEVICES FOR TREATING SKIN Lions
EP1664051A4 (en) PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USING SAME FOR TREATING PROLIFERATION DISORDERS
AU2003223380A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
EP1487446A4 (en) BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES
SI1685125T1 (sl) Derivati pirola, primerni za zdravljenje proliferativnih bolezni
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
EP1812077A4 (en) MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
PT1670482E (pt) Utilização de ciclesonida para o tratamento de doenças respiratórias
EP1624786A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF ILLNESSES OF BIOLOGICAL CHANNELS
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2003240545A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
IL164951A0 (en) The treatment of pain with lfendropil
IL175611A0 (en) Combinations for the treatment of proliferative diseases
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
GB0216097D0 (en) Treatment of proliferative disorders
GB0325957D0 (en) The treatment of pain
GB0322014D0 (en) The treatment of pain
GB0303287D0 (en) Body treatment product